Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens

  • T. Schioppo Division of Clinical Rheumatology, ASST Pini-CTO, Milano, Italy; Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Italy.
  • L. Scalone Centro di Studio e Ricerca sulla Sanità Pubblica (CESP), Università degli Studi di Milano Bicocca, Monza, Italy; Fondazione CHARTA, Milano, Italy.
  • P. Cozzolino Centro di Studio e Ricerca sulla Sanità Pubblica (CESP), Università degli Studi di Milano Bicocca, Monza, Italy.
  • L. Mantovani Centro di Studio e Ricerca sulla Sanità Pubblica (CESP), Università degli Studi di Milano Bicocca, Monza, Italy; Fondazione CHARTA, Milano, Italy.
  • G. Cesana Centro di Studio e Ricerca sulla Sanità Pubblica (CESP), Università degli Studi di Milano Bicocca, Monza, Italy.
  • O. De Lucia Division of Clinical Rheumatology, ASST Pini-CTO, Milano, Italy.
  • A. Murgo Division of Clinical Rheumatology, ASST Pini-CTO, Milano, Italy.
  • F. Ingegnoli | francesca.ingegnoli@unimi.it Division of Clinical Rheumatology, ASST Pini-CTO, Milano, Italy; Department of Clinical Sciences & Community Health, Università degli Studi di Milano, Italy.

Abstract

Systemic sclerosis (SSc)-related Raynaud’s phenomenon (RP) and digital ulcers (DU) can impair health-related quality of life (HRQoL). The aim of our study was to estimate HRQoL in SSc patients treated with two different intravenous (IV) iloprost (ILO) regimens and in patients not treated with IV ILO. 96 consecutive SSc patients were enrolled in a pragmatic, prospective and non-randomized study, and divided into 3 groups: not requiring therapy with IV ILO (N=52), IV ILO once monthly (N=24) or IV ILO for 5 consecutive days every 3 months (N=20). Patients were followed up for three months. We assessed HRQoL using the generic preference-based questionnaire EQ-5D-5L. We conducted multiple regression analyses to estimate, in each treatment group, the mean general health (GH) and the mean utility index of the EQ-5D-5L, adjusting for possible confounders. The mean adjusted utility index and GH score, after three months’ follow-up, were not different in the three groups: IV ILO was able to make patients requiring IV ILO similar to those not requiring it. Moreover, there was no difference in this model between the two ILO regimens (1 day monthly vs 5 consecutive days every 3 months). The two different IV ILO regimens (the most appropriate regimen was decided according to patients’ characteristics and needs) were able to stabilize HRQoL in RP secondary to SSc non-adequately controlled by oral therapy.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2019-07-09
Info
Issue
Section
Articles
Keywords:
Iloprost, prostacyclin, systemic sclerosis, health related quality of life, EQ-5D-5L
Statistics
  • Abstract views: 663

  • PDF: 466
How to Cite
Schioppo, T., Scalone, L., Cozzolino, P., Mantovani, L., Cesana, G., De Lucia, O., Murgo, A., & Ingegnoli, F. (2019). Health-related quality of life burden in scleroderma patients treated with two different intravenous iloprost regimens. Reumatismo, 71(2), 62-67. https://doi.org/10.4081/reumatismo.2019.1190

Most read articles by the same author(s)